About us
Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis
Our pipelineDiscovering targeted medicines
Our lead asset is zelasudil (RXC007), a next-generation selective ROCK2 inhibitor, with potential in multiple interstitial lung diseases and other fibrotic indications including cancer-associated fibrosis, which is in an initial Phase 2 clinical programme in idiopathic pulmonary fibrosis patients. We have a further programme in our ROCK inhibitor portfolio, RXC008, a potential first-in-class GI-targeted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn’s disease, in which a Phase 1 healthy volunteer study has commenced. Our lead oncology asset, zamaporvint (RXC004), is in Phase 2 clinical development for patients with Wnt-ligand dependent tumours, in combination with anti-PD-1 therapy. In discovery, we have a pipeline of differentiated oncology and fibrosis research programmes and collaborations, driven by our world-class drug discovery engine.
Our core strengths in medicinal chemistry and translational science enable us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets. These strengths have been recognised by others, and we have successfully completed a number of partnering deals in recent years including with AstraZeneca, (Porcupine inhibitor, AZD5055 previously RXC006), Loxo Oncology ( FDA approved BTK inhibitor, JaypircaTM, pirtobrutinib/LOXO-305, previously RXC005) and multiple deals with Jazz (including Pan-RAF inhibitor, JZP815, and discovery stage KRAS Inhibitor programme).
Our team
Our notable team of in-house scientists is based at our headquarters at Alderley Park, Cheshire, the UK’s largest single site life science campus*. The team combines world-class skills in medicinal chemistry and translational science with deep-rooted biotech and large pharma experience, and has successfully generated numerous drug candidates and progressed them through discovery and into the clinic.
Business model & strategy
Exceptional capabilities in medicinal chemistry and translational science are the foundation of Redx. Our ambition is to create world leading medicines that will transform patients’ lives, by delivering better medicines faster.
We are building a leading biotechnology company through the development of novel and differentiated targeted medicines in cancer and fibrotic disease, and the emerging area of cancer-associated fibrosis, where we see the opportunity to be best-in-class, or first-in-class.
Key elements of our strategy
- Advance our clinical-stage ROCK inhibitor programmes:
- Zelasudil, a next-generation selective ROCK2 inhibitor, initially in a clinical trial in idiopathic pulmonary fibrosis (IPF) and then more broadly in Interstitial Lung Disease (ILD) with potential to explore additional fibrotic indications, including cancer-associated fibrosis.
- RXC008, a GI-targeted pan-ROCK inhibitor, currently in a Phase 1 healthy volunteer clinical study to be followed by a Phase 2 study in Crohn’s patients with fibrostenosis as a potential first-in-class treatment
- Invest in our Redx discovery engine to expand our pipeline, including advancing RXC009, a selective DDR1 inhibitor for kidney fibrosis through IND-enabling studies.
- Maximise full potential of our product pipeline by either retaining commercial rights or considering attractive development and commercialization partnerships. We aim to partner zamaporvint, our clinical stage Porcupine inhibitor, being developed as potential targeted treatment for Wnt-ligand dependent tumours in hard-to-treat GI cancers.
- Attract and retain the best people by providing a world-class environment.
Our validated discovery engine fuels our business model and incorporates our extensive in-house experience and knowledge with a network of specialist contractors to create differentiated drug candidates.
Our distinctive approach consistently enables us to generate, potential best-in-class or first-in-class drug candidates and is built around three steps:
1. Smart Target Selection
With the goal of de-risking our programmes, we select biologically or clinically validated targets where we believe there is an opportunity to successfully apply our drug discovery capabilities in diseases of high unmet medical need.
2. Differentiated Molecule Design
Create molecules with differentiated properties, leveraging our design frameworks and our strength and experience in medicinal chemistry, computational design and translational biology to optimise a novel differentiated molecule for the target.
3. Translate
Focus our differentiated, targeted small molecules towards commercially attractive markets in which we believe we can be successful.
Our values
At Redx, our ambition is to create world leading medicines that will transform patients’ lives, by delivering better medicines faster.
Our core strengths in medicinal chemistry and translational science enable us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is the opportunity to create best-in-class or first-in-class drug candidates for diseases of unmet medical need.
Our five core company values underpin everything we do.
High Standards
We stand or fall by quality data
Resilience
We can’t win by giving up
Teamwork
Together we are stronger
Innovation
Bright ideas fuel our pipeline
Agility
The market waits for no-one